Abliva’s CEO to BioStock: “One step closer to a marketed medicine”

Abliva has reported positive interim analysis results for the potentially registrational FALCON study, assessing KL1333 in patients with primary mitochondrial disease. While validating the study design and confirming KL1333’s strong safety profile, it also triggers a convertible loan conversion, providing Abliva with proceeds of 42 million SEK before transaction costs.
– The interim analysis is an important de-risking event for the program, says Ellen K. Donelly, CEO of Abliva.

Read the full interview with Ellen K. Donelly at biostock.se:

https://www.biostock.se/en/2024/07/ablivas-ceo-one-step-closer-to-a-marketed-medicine/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/